BACKGROUND In driver gene-negative non-small cell lung cancer patients who relapse following radical resection,combination chemotherapy using bevacizumab and platinumbased dual drugs is known to increase both progress...BACKGROUND In driver gene-negative non-small cell lung cancer patients who relapse following radical resection,combination chemotherapy using bevacizumab and platinumbased dual drugs is known to increase both progression-free and overall survival.Treatment initially includes bevacizumab,and if patients are able to tolerate it,bevacizumab can continue to be utilized until disease progression.Bevacizumab is a recombinant humanized monoclonal neutralizing antibody that acts against vascular endothelial growth factor(VEGF).Various anti-VEGF monoclonal antibodies,such as bevacizumab,can increase the risk of arterial thromboembolism.Current data indicate that VEGF-targeted treatment does not significantly increase the risk of venous thromboembolism events,except for bevacizumab.CASE SUMMARY A 55-year-old man underwent radical resection for cancer of the right lung.Six months following surgery,multiple metastases were observed in his left lung.Subsequently,six cycles of bevacizumab combined with pemetrexed/carboplatin chemotherapy was given.Efficacy evaluation continued to be partial relief according to RECIST 1.1 standards,and no noticeable adverse reactions were noted.After three cycles of maintenance therapy using a combination of bevacizumab and pemetrexed,the patient developed dizziness and dyspnea.The patient was diagnosed with acute cerebral infarction and pulmonary embolism following head magnetic resonance imaging,computed tomography(CT)angiography,and chest enhanced CT.Although the patient received lowmolecular-weight heparin anticoagulation and other treatment,the patient eventually died of respiratory failure 1 mo later.This case report may offer some insight into fatal arteriovenous embolism,which has not been previously reported.CONCLUSIONBevacizumab combined with chemotherapy may also increase the risk of arteriovenousthromboembolism. Accordingly, patients who receive angiogenesis inhibitor therapy should becarefully selected. Furthermore, close monitoring and timely intervention are necessary in order toreduce the risk of such toxicities.展开更多
To the Editor： Venous thromboembolism （VTE）, including deep vein thrombosis and pulmonary embolism, is a common complication in cancer patients, and the overall risk of VTE in patients with a malignancy was 7-fold ...To the Editor： Venous thromboembolism （VTE）, including deep vein thrombosis and pulmonary embolism, is a common complication in cancer patients, and the overall risk of VTE in patients with a malignancy was 7-fold as high as that for patients without cancer. Herein, we report a case of long-term survival associated with crizotinib in an anaplastic lymphoma kinase （ALK）-positive lung cancer patient with a pulmonary artery embolism.展开更多
文摘BACKGROUND In driver gene-negative non-small cell lung cancer patients who relapse following radical resection,combination chemotherapy using bevacizumab and platinumbased dual drugs is known to increase both progression-free and overall survival.Treatment initially includes bevacizumab,and if patients are able to tolerate it,bevacizumab can continue to be utilized until disease progression.Bevacizumab is a recombinant humanized monoclonal neutralizing antibody that acts against vascular endothelial growth factor(VEGF).Various anti-VEGF monoclonal antibodies,such as bevacizumab,can increase the risk of arterial thromboembolism.Current data indicate that VEGF-targeted treatment does not significantly increase the risk of venous thromboembolism events,except for bevacizumab.CASE SUMMARY A 55-year-old man underwent radical resection for cancer of the right lung.Six months following surgery,multiple metastases were observed in his left lung.Subsequently,six cycles of bevacizumab combined with pemetrexed/carboplatin chemotherapy was given.Efficacy evaluation continued to be partial relief according to RECIST 1.1 standards,and no noticeable adverse reactions were noted.After three cycles of maintenance therapy using a combination of bevacizumab and pemetrexed,the patient developed dizziness and dyspnea.The patient was diagnosed with acute cerebral infarction and pulmonary embolism following head magnetic resonance imaging,computed tomography(CT)angiography,and chest enhanced CT.Although the patient received lowmolecular-weight heparin anticoagulation and other treatment,the patient eventually died of respiratory failure 1 mo later.This case report may offer some insight into fatal arteriovenous embolism,which has not been previously reported.CONCLUSIONBevacizumab combined with chemotherapy may also increase the risk of arteriovenousthromboembolism. Accordingly, patients who receive angiogenesis inhibitor therapy should becarefully selected. Furthermore, close monitoring and timely intervention are necessary in order toreduce the risk of such toxicities.
文摘To the Editor： Venous thromboembolism （VTE）, including deep vein thrombosis and pulmonary embolism, is a common complication in cancer patients, and the overall risk of VTE in patients with a malignancy was 7-fold as high as that for patients without cancer. Herein, we report a case of long-term survival associated with crizotinib in an anaplastic lymphoma kinase （ALK）-positive lung cancer patient with a pulmonary artery embolism.
